Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2004 2
2005 2
2006 1
2009 1
2013 1
2016 2
2017 4
2018 1
2019 2
2020 5
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Advanced Kidney Medullary Carcinoma"
Page 1
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. Araque KA, et al. Horm Metab Res. 2020 Aug;52(8):562-577. doi: 10.1055/a-1089-7870. Epub 2020 Feb 10. Horm Metab Res. 2020. PMID: 32040962 Free PMC article. Review.
This review compiles newer concepts in diagnosis, stratification tools and treatment options for patients with differentiated thyroid cancer (DTC), medullary thyroid carcinoma (MTC) and anaplastic thyroid cancer (ATC). ...Several immunotherapeutic agents are being a …
This review compiles newer concepts in diagnosis, stratification tools and treatment options for patients with differentiated thyroid cancer …
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Tykodi SS, Gordan LN, Alter RS, Arrowsmith E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ, Hutson T, Zhang J, Zoco J, Johansen JL, Rezazadeh Kalebasty A. Tykodi SS, et al. J Immunother Cancer. 2022 Feb;10(2):e003844. doi: 10.1136/jitc-2021-003844. J Immunother Cancer. 2022. PMID: 35210307 Free PMC article. Clinical Trial.
BACKGROUND: CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features mostly exclude …
BACKGROUND: CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly …
SMARCB1 regulates the hypoxic stress response in sickle cell trait.
Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. Soeung M, et al. Proc Natl Acad Sci U S A. 2023 May 23;120(21):e2209639120. doi: 10.1073/pnas.2209639120. Epub 2023 May 15. Proc Natl Acad Sci U S A. 2023. PMID: 37186844 Free PMC article.
Renal medullary carcinoma (RMC) is an aggressive kidney cancer that almost exclusively develops in individuals with sickle cell trait (SCT) and is always characterized by loss of the tumor suppressor SMARCB1. Because renal ischemia induced by red blood cell s …
Renal medullary carcinoma (RMC) is an aggressive kidney cancer that almost exclusively develops in individuals with sic …
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.
Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Msaouel P, et al. Cancer Cell. 2020 May 11;37(5):720-734.e13. doi: 10.1016/j.ccell.2020.04.002. Epub 2020 Apr 30. Cancer Cell. 2020. PMID: 32359397 Free PMC article.
Renal medullary carcinoma (RMC) is a highly lethal malignancy that mainly afflicts young individuals of African descent and is resistant to all targeted agents used to treat other renal cell carcinomas. ...
Renal medullary carcinoma (RMC) is a highly lethal malignancy that mainly afflicts young individuals of African descent and is …
Cabozantinib for the treatment of kidney cancer.
Abdelaziz A, Vaishampayan U. Abdelaziz A, et al. Expert Rev Anticancer Ther. 2017 Jul;17(7):577-584. doi: 10.1080/14737140.2017.1344553. Expert Rev Anticancer Ther. 2017. PMID: 28633552 Free PMC article. Review.
Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line t …
Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recentl …
Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
Hacking SM, Pavlick D, Wang Y, Carneiro BA, Mullally M, Lu S, Canepa M, Bratslavsky G, Jacob J, Necchi A, Spiess PE, Wang L, Yakirevich E, Ross J. Hacking SM, et al. Oncologist. 2023 Jul 5;28(7):e508-e519. doi: 10.1093/oncolo/oyad040. Oncologist. 2023. PMID: 36917021 Free PMC article.
Genomic alterations (GA) in NF2 tumor-suppressor gene have been associated with aggressive behavior in kidney tumors. We used comprehensive genomic profiling (CGP) to evaluate the frequencies of NF2 GA in histologic subtypes of kidney tumors and co-occurring GA in o …
Genomic alterations (GA) in NF2 tumor-suppressor gene have been associated with aggressive behavior in kidney tumors. We used compreh …
The history of urologic pathology: an overview.
Young RH, Eble JN. Young RH, et al. Histopathology. 2019 Jan;74(1):184-212. doi: 10.1111/his.13753. Histopathology. 2019. PMID: 30565309 Review.
Sesterhenn, has contributed to knowledge of renal neoplasia with articles of note on oncocytoma, metanephric adenoma, and medullary carcinoma. In the mid-1980s, the German workers Wolfgang Thoenes and Stephan Storkel recognised the distinctive tumour known as chromo …
Sesterhenn, has contributed to knowledge of renal neoplasia with articles of note on oncocytoma, metanephric adenoma, and medullary …
Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.
Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, Fassnacht M. Kroiss M, et al. J Clin Endocrinol Metab. 2020 May 1;105(5):1461-8. doi: 10.1210/clinem/dgz318. J Clin Endocrinol Metab. 2020. PMID: 31900481 Free PMC article.
BACKGROUND: Objective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is only ~20% and early tumor progression is frequent. ...Cabozantinib (CABO) is an inhibitor of c-MET, vascular endothelial growth factor recepto …
BACKGROUND: Objective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is on …
Advanced nccRCC: what therapeutic options in 2022?
Bigot C, Boudier P, Ladoire S, Barthélémy P. Bigot C, et al. Bull Cancer. 2022 May;109(2S):2S39-2S46. doi: 10.1016/S0007-4551(22)00237-5. Bull Cancer. 2022. PMID: 35760469
Papillary renal cell carcinomas (pRCC) are the most frequent subtype with 15% to 20% of all kidney cancers. Improved biological knowledge of these tumours has led to better identification of each subtype. ...We propose to present throughout this article the latest availabl …
Papillary renal cell carcinomas (pRCC) are the most frequent subtype with 15% to 20% of all kidney cancers. Improved biological knowl …
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.
Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P; ISUP Renal Tumor Panel. Srigley JR, et al. Am J Surg Pathol. 2013 Oct;37(10):1469-89. doi: 10.1097/PAS.0b013e318299f2d1. Am J Surg Pathol. 2013. PMID: 24025519
The hybrid oncocytic chromophobe tumor, which is an indolent tumor that occurs in 3 settings, namely Birt-Hogg-Dube Syndrome, renal oncocytosis, and as a sporadic neoplasm, was placed, for the time being, within the chromophobe RCC category. Recent advances related to coll …
The hybrid oncocytic chromophobe tumor, which is an indolent tumor that occurs in 3 settings, namely Birt-Hogg-Dube Syndrome, renal oncocyto …
26 results